What question did this study set out to answer?

This research examines the long-term effects of chemoresection with mitomycin C for treating recurrent non-muscle-invasive bladder cancer (NMIBC).

March 24, 2026Open Access

DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non–muscle-invasive Bladder Cancer

Key Points

This research examines the long-term effects of chemoresection with mitomycin C for treating recurrent non-muscle-invasive bladder cancer (NMIBC).
Conducted a five-year follow-up of a randomized controlled trial
Evaluated oncological outcomes in patients receiving chemoresection with mitomycin C
Compared results to traditional surgical interventions
Chemoresection significantly reduced the need for invasive surgical procedures
Long-term oncological outcomes were maintained
Integration of this treatment is supported for selected patients

Abstract

Chemoresection reduces the need for surgical procedures in patients with recurrent NMIBC without compromising long-term oncological outcomes. These findings support its integration as a less-invasive treatment option in selected patients.

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper